Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting.

OBJECTIVE: We aimed to assess the impact of Nottingham grade (NG) on breast cancer specific survival (BCSS) and recurrence free survival (RFS) of operable breast cancer (BC) patients presenting at different TNM stages in view of assessing the value of NG in prognostication of breast cancer in the Sri Lankan setting.

METHOD: This retro-prospective study included a consecutive series of TNM stage I to III BC patients presented to our unit from 2006 to 2012. Data were collected through follow up visits, clinic and laboratory records. Grading and scoring of oestrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (Her2) expressions were done by a single investigator. Kaplan-Meier and Cox-regression models were used in the survival analysis.

RESULTS: A total of 742 (NG1-12%; NG2-45%; NG3-43%) patients with a median follow up of 39.5 (range: 12 - 138) months were included. Five-year BCSS was 94%-NG1, 80%-NG2 and 72%-NG3 (p < 0.001). Five-year RFS was 86%-NG1, 75%-NG2 and 67%-NG3 (p = 0.001). Only the lymph-node status (LNS) (p = 0.001) had an independent effect on the BCSS and RFS of NG3 patients. LNS (p = 0.001), PR (p = 0.004) and Her2 (p < 0.001) independently affected the BCSS of NG2 patients. None of the factors considered had an effect on the BCSS/RFS of NG1 patients. A significant decrease in BCSS and RFS was seen with an increase in NG in the sub-group of TNM stage III (p = 0.01 and 0.011).

CONCLUSION: NG categorizes BC patients into prognostic groups with distinctly different survival outcomes. Sub-categorization of TNM stage III by NG is suggested.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app